$102.50
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 646 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
Country

US

CEO

Mr. George Lemaitre

IPO date

2006

Employees

646

ISIN

US5255582018

Key stats

Open

$102.50

Volume

177.91K

Market cap

$2.33B

Prev. close

$102.40

Impl / hst vl

-

Open interest

$0.00

$102.50

Day’s Range

$102.50

$79.40

52W Range

$118.01

Valuation

44
Valuation score
Fairly Valued
P/E
37.93
P/S
9.24
P/B
5.82
Current ratio
14.32
Debt / Equity
0.35
ROE
16.19%
Gross margin
72.72%
Income growth
0.62%
FCF growth
-42.42

Jun

4

Dividends

The last payment date was Jun 4, 2026

Div. per Share

$0.25

Div. Yield

0.25%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Strong buy

The average rating from top 5 analysts indicates that stock may significantly outperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$121.13
The top 10 analysts forecasts that 12-month price may increase by 18.17%, with a low of $103.02 and a high of $141.75
$103.02
Low
$121.13
Avg
$141.75
High
Current price

Earnings

Q1 ‘26 revenue
$66.55M
Q1 ‘26 net income
$15.68M
Revenue
Net income
Previous EPS
$0.68
Estimate EPS
$0.82
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply